2021 Conference

2021: qEEG and LORETA Monitoring of Repetitive Transcranial Magnetic Stimulation for Medication Resistant Depression (Plenary)

Abstract:Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for medication resistant depression (Boes et al., 2018; Trapp et al., 2020). Numerous studies have investigated the neurophysiological, neuroanatomical and functional connectivity effects relative to rTMS (Bailey et al., 2019; Ge, Downar, Blumberger, Daskalakis, & Vila- Rodriguez, 2020; Keuper, Terrighena, Chan, Junghoefer, & Lee, 2018; Noda […]

2021: qEEG and LORETA Monitoring of Repetitive Transcranial Magnetic Stimulation for Medication Resistant Depression (Plenary) Read More »

2021: Update on CPT Coding and Insurance Reimbursement (Plenary)

Abstract:This presentation will focus on recent developments in CPT coding and insurance reimbursement for neurofeedback and QEEG. The topics covered will include: history of CPT codes to date, proposed changes to current CPT codes with rationale, modifiers for CPT codes (non-covered service, telehealth, etc) and the importance in using them, an update on insurance reimbursement

2021: Update on CPT Coding and Insurance Reimbursement (Plenary) Read More »

2021: Treating COVID-19 with Photobiomodulation – Short-term Recovery and Long-Haul Neuro-Regulation (Plenary)

Abstract:Considerable global effort has been directed towards vaccination to control the spread of COVID-19. While there is significant success in these preventative efforts, there is still a need to consider options to improve the outcomes of those who have been infected. This presentation discusses photobiomodulation (PBM) as such an option. PBM is increasingly used by

2021: Treating COVID-19 with Photobiomodulation – Short-term Recovery and Long-Haul Neuro-Regulation (Plenary) Read More »

2021: The Use of ERP/EEG Guided tACS/tRNS Neurostimulation Methods in Clinical Practice (Plenary)

Abstract:Over the past 20 years the use of QEEG brain mapping has been used to develop neurofeedback treatment strategies. The typical acquisition of the EEG involves eyes open and closed recordings where the subject is not engaged in any activity. Sixty seconds of artifact free data is selected and quantified into specific frequency bands and

2021: The Use of ERP/EEG Guided tACS/tRNS Neurostimulation Methods in Clinical Practice (Plenary) Read More »

2021: The State of NeuroMeditation: Historical Perspectives, Current Research and Future Directions (Plenary)

Abstract:From the earliest days of neurofeedback, clinicians have been using this technology to enhance states of meditation and improve mental health. In general, these early approaches focused on increasing the amplitude of alpha and/or theta. These strategies were used to guide the meditator into deeper states of consciousness, enhance creativity, and reduce anxiety. Eventually, these

2021: The State of NeuroMeditation: Historical Perspectives, Current Research and Future Directions (Plenary) Read More »

2021: Psychoneuroendocrinology of Aging: Implications for Neuroregulation (Plenary)

Abstract:Considering that life expectancy has increased over the last few years and that age is the main risk factor for the incidence of neurocognitive disorder (NCD), the characterization of the neurobiological substrates that constitute normal cognitive aging has become increasingly relevant, as well as the underpinnings of pathological cognitive aging. Aging is a multidimensional process,

2021: Psychoneuroendocrinology of Aging: Implications for Neuroregulation (Plenary) Read More »

2021: Principles of Noninvasive Neuromodulation in Neurological and Psychiatric Disorders

Abstract:Neuromodulation applied in neurological and psychiatric disorders is becoming an option for patients suffering from these conditions. Noninvasive brain stimulation (NIBS) development has been steady thanks to the evidence coming from clinical trials, and the technological advances that keep improving its efficacy and safety profile. The use of NIBS has significant advantages, such as the

2021: Principles of Noninvasive Neuromodulation in Neurological and Psychiatric Disorders Read More »

2021: Pilot Data Examining Induction of Suboxone and Monitoring with Quantitative EEG and LORETA methods (Plenary)

Abstract:Introduction: Quantitative electroencephalograph (qEEG) and low-resolution electromagnetic brain tomography (LORETA) methods are undervalued and underused for determining the effects of medications on the brain, especially concerning substance use disorders (Cannon, Lubar & Baldwin, 2008; Sokhadze, Cannon & Trudeau, 2008) and medication assisted therapies (MAT). Debate continues about MAT with drugs such as Suboxone despite positive

2021: Pilot Data Examining Induction of Suboxone and Monitoring with Quantitative EEG and LORETA methods (Plenary) Read More »

2021: Nurturing Awareness: Neurofeedback and Psychedelic Therapies (Plenary)

Abstract:Neurophenomenological studies are increasingly exploring the brain mechanisms through which psychedelic substances exert their mind-altering effects. A provocative question is whether such knowledge might be harnessed as a means of self-inducing altered states of consciousness by non-pharmacological means, for example through the combination of meditation practices and EEG neurofeedback. Ross et al., (2013) demonstrated that

2021: Nurturing Awareness: Neurofeedback and Psychedelic Therapies (Plenary) Read More »

2021: Normal EEG (Plenary)

Abstract:In neurotherapy we often look for abnormalities in brain function that are related to our clients’ struggles. Concurrently, there has been a trend in our field for a long time to rely on maps to make assessments; however, it is imperative as practitioners that we learn to look at the EEG to verify the features

2021: Normal EEG (Plenary) Read More »

Scroll to Top

Are you having problems clicking next on the membership form?

You must have 3rd party cookies set to “Always Accept.”

Internet Explorer 7 on Windows

  • Click the “Tools” menu
  • Click “Internet Options”
  • Select the “Privacy” tab
  • Option 1: To enable third-party cookies for all sites
  • Click “Advanced”
  • Select “Override automatic cookie handling”
  • Select the “Accept” button under “Third-party Cookies” and click “OK”

Firefox 3 on Windows

  • Click the “Tools” menu
  • Click “Options…”
  • Select the “Privacy” menu
  • Make sure “Keep until” is set to “they expire”
  • Option 1: To enable third party cookies for ALL sites: Make sure “Accept third-party cookies” is checked

Safari on Apple OS X:

  • Click the “Safari” menu
  • Click “Preferences…”
  • Click the “Security” menu
  • For “Cookies and website data” unselect “Block all cookies”
  • For “Website tracking”, unselect “Prevent cross-site tracking”
Safari enable cookies for membership purchase.

Firefox 3 on Apple OS X:

  • Click the “Firefox” menu
  • Click Preferences…
  • Click the Privacy menu
  • Make sure “Keep until” is set to “they expire”
  • Option 1: To enable third-party cookies for ALL sites: Make sure “Accept third-party cookies” is checked

Google Chrome on Windows

  • Select the Wrench (spanner) icon at the top right
  • Select “Options”
  • Select the “Under the Hood” tab
  • Select “Allow all cookies” under “Cookie Settings” and click “Close”

Internet Explorer 6 on Windows

  • Click the “Tools” menu
  • Click “Internet Options”
  • Select the “Privacy” tab
  • Move the settings slider to “Low” or “Accept all cookies”
  • Click “OK”

Opera 9 on Windows

  • Click the “Tools” menu
  • Click “Preferences…”
  • Click the “Advanced” tab
  • Select “Cookies” on the left list
  • Make sure “Accept cookies” is selected and uncheck “Delete new cookies when exiting Opera”
  • Click “OK”